Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma

被引:0
|
作者
Najam, Rahila [1 ]
Bano, Nusrat [1 ]
Mateen, Ahmed [2 ]
机构
[1] Univ Karachi, Fac Pharm, Dept Pharmacol, Karachi, Pakistan
[2] KIRAN, Karachi, Pakistan
关键词
Colorectal Carcinoma; Cardiac Toxicity; 5-FU; CPK; GOT; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR COMPLICATIONS; CANCER-THERAPY; 5-FLUOROURACIL; CARDIOTOXICITY; PATHOGENESIS; DIAGNOSIS; INFUSION; PATIENT;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of the study is evaluation and assessment of parameters of cardiac toxicity in patients subjected to 5-FU based chemotherapy. Cardiac morbidity is a reported outcome in different 5FU/LV regimens; however none of them are definite or proximate. The bimonthly regimen of high dose leucovorin is reported to be less toxic and more effective as compared to the monthly regimen of low dose leucovorin. We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion. The correlation of elevated cardiac biomarkers, angina and hypertension is comparatively assessed in patients with normal general status, hyperglycemia and known cardiac disorders subjected to two different 5FU based chemotherapeutic regimen.
引用
收藏
页码:1013 / 1022
页数:10
相关论文
共 50 条
  • [31] A Phase II Randomized Study of Two Doses of Vorinostat in Combination With 5-FU/LV in Patients With Refractory Colorectal Cancer (CRC)
    Fakih, M.
    Groman, A.
    McMahon, J.
    Romano, K.
    Wisniewski, M.
    Wilding, G.
    Fetterly, G.
    Muindi, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S423 - S423
  • [32] RANDOMIZATION STUDY OF 2 DIFFERENT SCHEDULES OF METHYL CCNU(MECCNU), 5-FLOUROURACIL (5-FU), AND VINCRISTINE(VCR) FOR METASTATIC COLORECTAL CARCINOMA
    KEMENY, N
    YAGODA, A
    GOLBEY, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 336 - 336
  • [33] Sequential treatment with cisplatin (P) in comibination with infusional 5-FU/LV (PFL) followed by irinotecan (IR)+5-FU/LV (IRFL) followed by docetaxel (T)+5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (GONO)
    Loupakis, F.
    Masi, G.
    Fontana, E.
    Picone, V
    Mentuccia, L.
    Granetto, C.
    Fea, E.
    Pfanner, E.
    Lencioni, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 95 - 95
  • [34] Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (IR)+5-FU/LV (IRFL) followed by docetaxel (T)+5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico NORD-OVEST (GONO)
    Loupakis, F.
    Masi, G.
    Fontana, E.
    Allegrini, G.
    Bursi, S.
    Barbara, C.
    Cerri, E.
    Barletta, M. T.
    Picone, V
    Mentuccia, L.
    Granetto, C.
    Fea, E.
    Pfanner, E.
    Murr, R.
    Brunetti, I
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI50 - XI50
  • [35] Successful treatment with 5-Fu
    Schechter, BA
    Nagler, RS
    OPHTHALMOLOGY, 2003, 110 (04) : 625 - 626
  • [36] Contracture Treatment With 5-FU
    Talei, Ben
    Raskin, Jonathan
    Borrelli, Michela
    Desales, Alexis
    ENT-EAR NOSE & THROAT JOURNAL, 2021, 100 (6_SUPPL) : 876S - 878S
  • [37] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Gianluca Masi
    Lorenzo Fornaro
    Enrico Vasile
    Giacomo Allegrini
    Eloise Fontana
    Cristina Granetto
    Lisa Salvatore
    Lucia Mentuccia
    Michele Andreuccetti
    Enrico Cortesi
    Marco Merlano
    Stefano Cascinu
    Alfredo Falcone
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 559 - 566
  • [38] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Loupakis, Fotios
    Masi, Gianluca
    Fornaro, Lorenzo
    Vasile, Enrico
    Allegrini, Giacomo
    Fontana, Eloise
    Granetto, Cristina
    Salvatore, Lisa
    Mentuccia, Lucia
    Andreuccetti, Michele
    Cortesi, Enrico
    Merlano, Marco
    Cascinu, Stefano
    Falcone, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 559 - 566
  • [39] Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
    Taïeb, J
    Mitry, E
    Boige, V
    Artru, P
    Ezenfis, J
    Lecomte, T
    Clavero-Fabri, MC
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1192 - 1196
  • [40] A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer.
    Redlinger, M
    Kramer, A
    Flaherty, K
    Sun, W
    Haller, D
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S